Rinsho Ganka Volume 64, Issue 7 (July 2010)

A case of psoriatic panuveitis treated by systemic infliximab Mari Goto 1 , Hiroshi Ujihara 1 , Masao Matsubara 1 1Dept of Ophthalmol,Tokyo Women's Med Univ Med Cent East pp.1165-1168
Published Date 2010/7/15
DOI https://doi.org/10.11477/mf.1410103267
  • Abstract
  • Look Inside
  • Reference

Abstract. Background:Tumor necrosis factor α(TNFα)is involved in the pathogenesis of psoriasis. Infliximab is an anti-TNFα monoclonal antibody. Purpose:To report a case of psoriatic panuveitis treated by systemic infliximab. Case:A currently 71-year-old female was first seen for anterior uveitis in both eyes 15 years ago. She had been treated with systemic steroid and cyclosporin for pustular psoriasis involving the skin and joints for 2 years. She received cataract surgery in the left eye 5 years before and in the right one year before. Visual acuity improved to 0.6 and 0.4 respectively. Panuveitis occurred 10 months ago with visual acuity worsening to 0.1 bilaterally. She started receiving intravenous injection of 3 mg/kg infliximab 7 months ago. The first injection was followed by improvement of skin and arthritic manifestations the following day and visual acuity also improved. She has been doing well for 7 months until present. Conclusion:Intravenous injection of infliximab was followed by improvement of panuveitis,skin and joint lesions in a patient with psoriasis.

Copyright © 2010, Igaku-Shoin Ltd. All rights reserved.


64巻7号 (2010年7月)
電子版ISSN 1882-1308 印刷版ISSN 0370-5579 医学書院